Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...
ALS is an incurable nervous system disease that causes the loss of muscle control. A research team at the University of ...
Performing a quality patient assessment is not limited to an ALS skill, but rather is an EMS skill in which all levels of providers need to be proficient. While ALS providers do obtain much more ...
“This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address Amyotrophic Lateral Sclerosis (ALS), which is a fatal neurodegenerative disease," said Zydus' ...
The ALS Association this summer will host the second edition of its ALS Nexus, a conference bringing together researchers, healthcare professionals, advocates, patients, and caregivers in a quest to ...
The multiple ascending dose trial is expected to recruit 48 patients with ALS and administer up to four doses of placebo or AMX0114 per participant. Amylyx expects early cohort data to be ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neurofilament light chain and cerebrospinal fluid ...
The multicentre, multiple ascending dose trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in 48 ALS patients. Patients will be randomised on a 3:1 ratio ...
Medicare patients referred to a neurologist had to wait a median of 34 days before being seen, and nearly 1 in 5 patients waited more than 90 days, in 2018 and 2019, according to a study published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback